Skip to main content

Advertisement

Table 2 Comparison of the frequency: demographical and clinical data in aRibP-positive and negative SLE patientsa

From: Diagnostic value and clinical laboratory associations of antibodies against recombinant ribosomal P0, P1 and P2 proteins and their native heterocomplex in a Caucasian cohort with systemic lupus erythematosus

   aRibP N H aRibP R 0 aRibP R 1 aRibP R 2
Clinical data All patients (n= 163) Positive (n= 30) Negative (n= 133) P value Positive (n= 34) Negative (n= 129) P value Positive (n= 24) Negative (n= 139) P value Positive (n= 28) Negative (n= 135) P value
Demographics              
   Age in years,b median 37.0 36.5 37.0 0.317 35.0 37.0 0.081 35.0 37.0 0.326 37.0 37.0 0.467
   Age at onset,c <18 years, % 19.7 15.6 13.9 1.000 24.3 16.8 0.338 22.2 17.7 0.592 26.7 16.7 0.203
   Females,c % 89.8 84.4 91.2 0.324 89.2 90 1.000 96.3 88.7 0.314 90 89.9 1.000
   SLE duration in months,b median 108.0 97.0 109.0 0.716 69.0 109.0 0.118 62.0 109.0 0.147 96.0 107.0 0.756
ACR criteria n = 163 n = 30 n = 133   n = 34 n = 129   n = 24 n = 139   n = 28 n = 135  
   Number of ACR criteria,b median 6.00 7.00 d 6.00 d 0.031 d 7.00 6.00 0.059 6.50 6.00 0.236 7.00 6.00 0.076
   Malar rash,c % 66.2 73.3 64.6 0.402 70.6 65.1 0.684 70.8 65.5 0.815 71.4 65.2 0.662
   Discoid rash,c % 12.3 16.7 11.3 0.536 14.7 11.6 0.571 16.7 11.5 0.501 25.0 9.63 0.0504
   Photosensitivity,c % 46.6 63.3 d 42.9 d 0.046 d 58.8 43.4 0.125 62.5 43.9 0.121 53.6 45.2 0.533
   Oral ulcers,c % 18.4 23.3 17.3 0.441 23.5 17.1 0.456 12.5 19.4 0.573 17.9 18.5 1.000
   Arthritis,c % 84.1 90.0 82.7 0.417 94.1 81.4 0.111 91.7 82.7 0.373 96.4 81.5 0,0506
   Serositis,c % 44.2 36.7 45.9 0.419 38.2 45.7 0.561 41.7 44.6 0.828 39.3 45.2 0.677
   Renal disorder,c % 42.9 46.7 42.2 0.686 44.1 42.6 1.000 37.5 43.9 0.658 39.3 43.7 0.834
   Epilepsy or psychosis,c % 12.9 20.0 11.3 0.228 14.7 12.4 0.774 25.0 10.8 0.091 21.4 11.1 0.209
   Hematologic,c % 63.8 70.0 62.4 0.530 67.6 62.8 0.690 58.3 64.7 0.646 67.9 62.9 0.672
   Immune disorder and ANA, % 100 100 100 - 100 100 - 100 100 - 100 100 -
SLEDAI n = 101 n = 17 n = 84   n = 22 n = 79   n = 17 n = 84   n = 17 n = 84  
   SLEDAI,b median 6.00 6.00 6.00 0.517 6.00 6.00 0.886 6.00 6.00 0.915 6.00 6.00 0.256
   Vasculitis,c % 7.92 5.89 8.33 1.000 4.55 8.86 0.682 11.8 7.14 0.621 5.89 8.33 1.000
   Arthritis,c % 33.7 23.5 35.7 0.408 22.7 36.7 0.309 11.8 d 38.1 d 0.048 d 11.8 d 38.1 d 0.048 d
   Hematuria,c % 6.93 11.8 5.95 0.335 4.55 7.59 1.000 0.00 9.52 0.346 0.00 9.41 0.346
   Proteinuria,c % 9.90 17.6 8.33 0.366 9.09 10.1 1.000 5.88 10.7 1.000 5.88 10.7 1.000
   Exanthema,c % 32.7 11.8 36.9 0.0503 27.3 34.2 0.615 23.5 34.5 0.572 23.5 34.5 0.572
   Alopecia,c % 16.8 23.5 15.5 0.478 27.3 13.9 0.195 17.6 16.7 1.000 17.6 16.7 1.000
   Pericarditis,c % 6.93 5.88 7.14 1.000 9.09 6.33 0.645 11.8 5.95 0.335 5.88 7.14 1.000
   Complement deficiency,c % 57.4 64.7 55.9 0.597 68.2 51.2 0.331 58.8 57.1 1.000 64.7 55.9 0.597
   Fever,c % 3.96 0.00 4.67 1.000 4.55 3.79 1.000 0.00 4.76 1.000 0.00 4.76 1.000
Drugs              
   Prednisolone,c % 89.9 93.1 89.2 0.738 90.9 89.7 1.000 86.9 90.4 0.706 88.9 90.3 0.734
   Azathioprine,c % 30.8 27.6 31.5 0.825 36.4 29.4 0.526 17.4 33.1 0.151 29.6 31.1 1.000
   Cyclophosphamide,c % 8.81 6.89 9.23 1.000 12.1 7.94 0.491 18.8 7.75 0.155 11.1 8.33 0.708
   Mycophenolate mofetil,c % 20.5 20.7 19.7 1.000 15.2 22.2 0.474 30.4 19.1 0.265 22.2 20.5 0.799
   Methotrexate,c % 3.04 3.23 3.01 1.000 8.33 1.56 0.071 7.69 2.17 0.179 3.45 2.96 1.000
   Hydroxychloroquine sulfate,c % 35.4 50.0 32.3 0.085 36.4 35.2 1.000 30.4 36.3 0.645 37.0 35.1 0.829
Laboratory              
   Leukocytes,b median 6.50 7.03 6.40 0.539 7.00 6.30 0.136 6.58 6.40 0.479 6.50 6.49 0.933
   Lymphocytes,b median 0.87 0.67 0.87 0.164 0.63 d 0.92 d 0.036 d 0.91 0.86 0.957 0.70 0.93 0.076
   Monocytes,b median 0.35 0.34 0.35 0.769 0.33 0.35 0.584 0.48 0.35 0.301 0.31 0.35 0.540
   ALT,b,e median 19.4 14.4 20.0 0.501 22.0 19.2 0.824 20.7 19.0 0.661 14.7 20.0 0.547
   AST,b,e median 25.0 28.0 24.9 0.212 25.5 25.0 0.953 27.5 24.9 0.129 25.0 25.0 0.568
   GGT,b,e median 23.0 26.0 21.6 0.278 24.0 21.1 0.423 29.0 d 21.0 d 0.047 d 29.0 21.1 0.108
   Low C3,c % 47.6 65.5 d 43.2 d 0.038 d 58.1 44.8 0.227 54.2 46.3 0.511 61.5 44.6 0.134
   Low C4,c % 34.7 37.9 33.9 0.670 38.7 33.6 0.672 37.5 34.1 0.816 38.4 33.9 0.656
   CRP,b median 0.38 0.30 0.40 0.771 0.28 0.42 0.454 0.25 0.42 0.379 26.0 25.9 0.803
   ESR,b median 24.0 25.0 24.0 0.616 22.0 25.0 0.740 21.5 25.0 0.572 23.0 24.5 0.819
Autoantibodies              
   High anti-Sm,c % 33.7 63.3 d 27.1 d 4 × 10 -3d 70.6 d 24.2 d <10 -4d 66.7 d 28.1 d 7 × 10 -3d 60.7 d 28.1 d 0.002 d
   Increased anti- dsDNA in ELISA,c % 42.3 70.0 d 36.8 d 0.002 d 67.8 d 36.4 d 0.002 d 75.0 d 37.4 d 7 × 10 -3d 60.7 d 39.3 d 0.058 d
   Increased anti- dsDNA in RIA,c % 56.4 76.7 d 51.9 d 0.015 d 79.4 d 50.4 d 0.003 d 83.3 d 51.8 d 0.004 d 78.6 d 51.9 d 0.012 d
   Increased anti- U1-RNP in anamnesis,c % 28.9 59.1 d 21.7 d 0.001 d 50.0 d 23.3 d 0.021 d 62.5 d 23.5 d 0.003 d 54.5 d 22.7 d 0.007 d
   Increased anti- nucleosomes,c % 50.9 60.0 48.9 0.315 64.7 47.3 0.084 62.5 48.9 0.271 70.4 d 47.1 d 0.035 d
   Increased anti- Ro/SS-A,c % 40.5 50.0 38.3 0.304 41.2 40.3 1.000 37.5 41.0 0.824 39.3 40.7 1.000
   Increased anti- La/SS-B,c % 12.3 20.0 10.5 0.213 8.82 13.2 0.769 0.00 d 14.4 d 0.046 d 3.57 14.1 0.203
  1. aSLE, systemic lupus erythematosus; ACR, American College of Rheumatology; ANA, antinuclear antibody; SLEDAI, Systemic Lupus Erythematosus Disease Activity Index; ALT, alanine aminotransferase; AST, aspartate aminotransferase; GGT, γ-glutamyl transpeptidase; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; ELISA, enzyme-linked immunosorbent assay; RIA, radioimmunoassay; anti-Sm, anti-Smith antibody; anti-dsDNA, anti-double-stranded DNA antibody; Ro/SS-A, anti- Sjögren's syndrome antigen A; La/SS-B, anti- Sjögren's syndrome antigen B; U1-RNP, U1-ribonucleoprotein; aRibP, anti-ribosomal P protein antibody; aRibPNH, antibodies against native ribosomal P heterocomplex; aRibPR0, antibodies against recombinant ribosomal P0 protein; aRibPR1, antibodies against recombinant ribosomal P1 protein; aRibPR2, antibodies against recombinant ribosomal P2 protein. All used autoantibody cutoffs were read out of receiver-operating characteristics analysis at a specificity of 98% (see Table 1); bP values were calculated using the Mann-Whitney U test; cP values were calculated using Fisher's exact test; dstatistically significant findings, highlighted in bold; eGGT values of men and from other laboratories have been standardized on cutoffs of GGT for women at the Charité University Hospital.